Core C: Tissue and Histopathology Core will provide fundamental support services to the research investigators in the proposed UCSF Oral Cancer Research Center. The Core is an organized network of clinicians, pathologists, and technical staff whose aims are: (1) to make available human oral cancerous and precancerous tissues for applied research investigations, (2) to develop a patient database for correlation of patient outcome with molecular tumor markers, and (3) to provide basic technical and interpretive histologic and immunohistologic services to Center investigators. The Core will be directed by an experienced academic faculty: an oral pathologist assisted by a general pathologist and an oral clinical oncologist. Contributor-collaborators will be head and neck surgeons and oral medicine and oncology clinicians. A data manager and a laboratory technician will provide the necessary internal support services of patient follow-up and tissue management. Biopsies and surgical specimens with a diagnosis of oral epithelial dysplasia, carcinoma in situ, invasive carcinoma, and verrucal carcinoma will be included in the Core. Tissue will come from new patients treated at one of five UCSF clinical sites, and from the pathology archives of five UCSF hospitals and two large San Francisco oral pathology biopsy services (UCSF and University of the Pacific). A secondary source of tissue will be five additional California oral pathology services and two West Coast oral medicine clinics. More than 3,000 archived oral cancers and precancers are immediately available for study, and it is estimated that 125 new tumors will be accessioned annually from the San Francisco Bay Area for use in prospective studies. Banked tissues will support the research projects that are the substance of the proposed center, and they will also be fundamental to the collection of demographic and follow-up data for oral cancer and precancer patients.

National Institute of Health (NIH)
National Institute of Dental & Craniofacial Research (NIDCR)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Bortoluzzi, Marcelo C; Yurgel, Liliane S; Dekker, Nusi P et al. (2004) Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:698-704
Sethi, Neerja; Palefsky, Joel (2003) Treatment of human papillomavirus (HPV) type 16-infected cells using herpes simplex virus type 1 thymidine kinase-mediated gene therapy transcriptionally regulated by the HPV E2 protein. Hum Gene Ther 14:45-57
Stern, Robert; Shuster, Svetlana; Neudecker, Birgit A et al. (2002) Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 276:24-31
Mio, Kazuhiro; Stern, Robert (2002) Inhibitors of the hyaluronidases. Matrix Biol 21:31-7
Regezi, Joseph A; Ramos, Daniel M; Pytela, Robert et al. (2002) Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 38:332-6
Nicoll, Steven B; Barak, Ory; Csoka, Antonei B et al. (2002) Hyaluronidases and CD44 undergo differential modulation during chondrogenesis. Biochem Biophys Res Commun 292:819-25
Shuster, Svetlana; Frost, Gregory I; Csoka, Antonei B et al. (2002) Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer 102:192-7
Mio, K; Csoka, A B; Nawy, S S et al. (2001) Detecting hyaluronidase and hyaluronidase inhibitors. Hyaluronan-substrate gel and -inverse substrate gel techniques. Methods Mol Biol 171:391-7
Lin, G; Stern, R (2001) Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett 163:95-101
Nawy, S S; Csoka, A B; Mio, K et al. (2001) Hyaluronidase activity and hyaluronidase inhibitors. Assay using a microtiter-based system. Methods Mol Biol 171:383-9

Showing the most recent 10 out of 32 publications